细胞因子在脓毒症心肌功能障碍中的作用:一项转化系统评价与荟萃分析
该转化系统评价与荟萃分析检索MEDLINE、Embase、Cochrane和PubMed截至2024年12月,纳入39项体外、动物和人类研究(21项进入荟萃分析),评估细胞因子添加或阻断对脓毒症心肌收缩力的影响。体外/离体研究显示IL-1、IL-6和TNF-α暴露后心肌细胞收缩力显著降低;动物研究显示TNF-α和IL-18与显著心脏抑制相关,IL-1效应不显著。人类研究显示脓毒症心肌功能障碍患者循环IL-6、IL-1、IL-8和IL-10水平高于对照,TNF-α差异不显著;两项小型干预研究提示细胞因子靶向治疗可能获益。作者结论认为临床数据仍为观察性,这些发现支持进一步开展靶向细胞因子的干预研究。
要点
- 体外/离体研究:暴露于IL-1后心肌细胞收缩力显著降低(SMD 5.62 [5.01;6.23]),IL-6(4.24 [1.49;6.99])和TNF-α(4.45 [3.17;5.72])同样显著降低。
- 动物研究:TNF-α(SMD 5.06 [1.46;8.65])和IL-18(1.56 [0.77;2.36])与显著心脏抑制相关,IL-1效应不显著(2.58 [-0.90;6.07])。
- 人类研究:脓毒症心肌功能障碍患者循环IL-6(SMD 0.51 [0.06;0.97])、IL-1(0.67 [0.11;1.23])、IL-8(0.59 [0.35;0.83])和IL-10(0.57 [0.34;0.80])水平高于对照,TNF-α差异不显著(0.63 [-0.02;1.28])。
- 两项小型干预研究提示细胞因子靶向治疗可能获益。
- 作者结论认为临床数据仍为观察性,这些发现支持进一步开展靶向细胞因子的干预研究。
适用人群与场景
- 纳入所有评估细胞因子调节对脓毒症心肌收缩力影响的细胞、动物和人类研究(描述性或干预性)。
- 缺乏收缩力评估的研究被排除出荟萃分析,但保留在系统评价中。
研究设计与关键结果
- 系统评价共纳入39项研究,其中21项进入荟萃分析。
- 11项体外或离体研究显示心肌细胞收缩力在暴露于IL-1(SMD 5.62 [5.01;6.23])、IL-6(4.24 [1.49;6.99])和TNF-α(4.45 [3.17;5.72])后显著降低,均纳入荟萃分析。
- 17项在体动物研究被审查,其中6项符合荟萃分析条件:TNF-α(SMD 5.06 [1.46;8.65])和IL-18(1.56 [0.77;2.36])与显著心脏抑制相关,而IL-1效应不显著(2.58 [-0.90;6.07])。
- 11项人类研究中4项纳入荟萃分析:脓毒症心肌功能障碍患者循环IL-6(SMD 0.51 [0.06;0.97])、IL-1(0.67 [0.11;1.23])、IL-8(0.59 [0.35;0.83])和IL-10(0.57 [0.34;0.80])水平高于对照,TNF-α差异不显著(0.63 [-0.02;1.28])。
- 两项小型干预研究提示细胞因子靶向治疗可能获益。
证据类型、等级与局限
- 证据类型:转化系统评价与荟萃分析,纳入体外、动物和人类研究。
- 采用随机效应模型汇总标准化均数差(SMD),使用针对各研究设计改编的专用工具评估偏倚风险。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现支持进一步开展靶向细胞因子的干预研究,以明确其在脓毒症心肌功能障碍中的作用。
- 临床数据仍为观察性,细胞因子靶向治疗尚未确立为脓毒症心肌功能障碍的推荐治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Septic myocardial dysfunction is a frequent complication of sepsis, commonly defined by impaired cardiac contractility. Despite its clinical significance, its pathophysiology remains poorly understood and no targeted therapy is currently available. Pro-inflammatory cytokines have been implicated in experimental models, but their causal role and therapeutic relevance in septic myocardial dysfunction remain uncertain. We aimed to systematically review and meta-analyze the impact of cytokine addition or blockade on myocardial function in sepsis across in vitro, in vivo, and human studies.
METHODS: We performed a systematic search of MEDLINE, Embase, Cochrane, and PubMed databases up to December 2024. We included all cellular, animal, and human studies (descriptive or interventional) assessing the effect of cytokine modulation on myocardial contractility in sepsis. Studies lacking contractility assessment were excluded from the meta-analysis but retained in the systematic review. Standardized mean differences (SMDs) were pooled using a random-effects model. Risk of bias was assessed using dedicated tools adapted to each study design.
RESULTS: A total of 39 studies were included in the systematic review, and 21 in the meta-analysis. Eleven in vitro or ex vivo studies showed that cardiomyocyte contractility was significantly reduced after exposure to IL-1 (SMD 5.62 [5.01;6.23]), IL-6 (4.24 [1.49;6.99]) and TNF-α (4.45 [3.17;5.72]); all were included in the meta-analysis. Seventeen in vivo animal studies were reviewed, of which six were eligible for meta-analysis: TNF-α (5.06 [1.46;8.65]) and IL-18 (1.56 [0.77;2.36]) were associated with significant cardiac depression, whereas IL-1 showed a non-significant effect (2.58 [-0.90;6.07]). Among eleven human studies, four were included in the meta-analysis. Patients with septic myocardial dysfunction had higher circulating levels of IL-6 (SMD 0.51 [0.06;0.97]), IL-1 (0.67 [0.11;1.23]), IL-8 (0.59 [0.35;0.83]) and IL-10 (0.57 [0.34;0.80]) than controls, while the difference for TNF-α was not significant (0.63 [-0.02;1.28]). Two small interventional studies suggested potential benefits from cytokine-targeting therapies.
CONCLUSIONS: This translational review supports a cytokine-mediated contribution to septic myocardial dysfunction. While mechanistic evidence is strong in preclinical models, clinical data remain observational. These findings justify further interventional studies targeting cytokines in septic myocardial dysfunction.
参考来源
- Frapard T, Gendreau S, Kasbi A, et al. The role of cytokines in septic myocardial dysfunction: a translational systematic review and meta-analysis. Ann Intensive Care. 2026. PMID: 41788499. doi:10.1016/j.aicoj.2026.100027
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。